Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

Thierry Facon • 11 Jun 2015
EHA 2015
Multiple Myeloma Lenalidomide

At the 20th Congress of the European Hematology Association (EHA), Thierry Facon, MD, of the University Hospital Hurriez, Lille, France, discusses the updated overall survival analysis of the FIRST study, which compared treatment with continuous lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, and thalidomide (MPT) in patients with newly diagnosed multiple myeloma.

More from Thierry Facon

5:09
Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates
Thierry Facon • 14 Jun 2019
3:23
Upcoming updates in multiple myeloma
Thierry Facon • 14 Jun 2019
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon • 11 Dec 2018
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon • 11 Dec 2018

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals